# INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder

> **NCT05644301** · PHASE3 · RECRUITING · sponsor: **Universiteit Antwerpen** · enrollment: 240 (estimated)

## Conditions studied

- Major Depressive Disorder
- Inflammation

## Interventions

- **DRUG:** Celecoxib
- **DRUG:** Minocyclin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05644301
- **Lead sponsor:** Universiteit Antwerpen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-21
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2024-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05644301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05644301, "INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05644301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*